Navigation Links
Survival rates for pediatric bone marrow transplants top in nation
Date:1/26/2012

The UCSF Benioff Children's Hospital has the best overall survival rates in the nation for bone marrow transplants, according to a recent independent review of 156 programs nationwide.

The Pediatric Blood and Marrow Transplant Program, led by Morton Cowan, MD, was ranked number one for survival performance by the federally mandated review program of the Center for International Blood and Marrow Transplant Research (CIBMTR).

The 156 transplant centers were reviewed based on the number of transplants done annually, adjusted for risk, and estimated the chance for survival one year post transplant. Overall, the estimated chance of survival after one year was 63.4 percent. Of the 156 centers reviewed, only 14 (9 percent) were considered over performers, with the UCSF Pediatric Bone Marrow Transplant Program ranked number one with a survival rate of 87.6 percent.

Additionally, the Adult Hematology and Blood and Marrow Transplant (BMT) at UCSF Medical Center was again named an "over performer" by the CIBMTR. This is the second consecutive year the service has been recognized as an over performer. The adult program is also one of 14 nationwide recognized for exceeding U.S. expectations in patient survival rates for those undergoing a blood or marrow transplant from either a relative or an unrelated donor. At UCSF, 75 percent of adult patients receiving a BMT survive at least a year, compared to the national average of 63.4 percent.

Christopher Dvorak, MD, a pediatric blood and bone marrow transplant specialist at the UCSF Benioff Children's Hospital, wasn't surprised by the results knowing firsthand the level of commitment to success that exists within and well beyond the pediatric BMT team.

"We work incredibly hard and have an attention to detail and dedication to our policies attempting to limit transplant-associated mortality," said Dvorak, who is also head of the national Pediatric Blood and Marrow Transplant Consortium's Supportive Care Strategy Sroup.

The UCSF pediatric BMT program has expanded in recent years by adding two physicians and two nurse practitioners, ultimately increasing the number of transplants performed. UCSF's interdisciplinary collaboration among health care professionals also adds a nuanced level of support. "Some of the credit for our success must go to the pediatric intensive care unit which helps patients survive when then get critically ill," Dvorak said.

The pediatric BMT unit also gives more individualized attention to the dosing of chemotherapy medications through increased interactions with the UCSF School of Pharmacy. "We have a great School of Pharmacy and now have a doctor of pharmacy on our team, helping us with tailoring the chemo regimens. We have great nurses and nurse practitioners through the School of Nursing as well, and all of that plays into our success."

While adult bone marrow transplants are usually performed to treat blood-related cancers, pediatric transplants are necessary for a host of other reasons. Immunodeficiency syndromes, defects in red blood cells, inborn errors of metabolism, and several types of cancer account for many of the BMT transplants performed in children at UCSF.


'/>"/>
Contact: Juliana Bunim
juliana.bunim@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related medicine news :

1. Gene Mutations May Boost Ovarian Cancer Survival: Study
2. Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years
3. Study showed oxaliplatin improved colon cancer patient survival
4. Drug improves survival of colorectal cancer patients, trial results show
5. Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
6. Personalized gene therapies may increase survival in brain cancer patients
7. Race, Gender, Dementia May Affect Parkinsons Survival
8. Demographic and clinical factors appear associated with survival in patients with Parkinsons disease
9. Ovarian cancer study proves drug delays disease progression, may improve survival
10. Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
11. Researchers identify potential target to delay metastatic pancreatic cancer and prolong survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Survival rates for pediatric bone marrow transplants top in nation
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Love is ... roses in a variety of colors, assortments and packaging. This staple for Valentine’s Day ... King Kullen location. , For Valentine’s Day, not only are long-stem roses available, ...
(Date:2/5/2016)... Falls, NY & Salt Lake City, UT (PRWEB) , ... February ... ... Davis, Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with ... on the New Really Cool Humans Amateur TV Network. , Each week, on his ...
(Date:2/5/2016)... ... ... The event is being held on April 7, 2016 from 5:30 p.m. to ... will fund nearly $100,000 for research for the care and cure of Parkinson’s disease. ... the architect of this informative event to raise awareness and funds for Parkinson’s. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco ... micro-needling services in their Napa Valley office. The technique utilizes the body’s own ... Dr. Canales and Dr. Furnas, are part of only a select few cosmetic ...
(Date:2/5/2016)... Dickson, Tennessee (PRWEB) , ... February 05, 2016 ... ... State Community College President George H. Van Allen have signed a joint enrollment ... semester, provides a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)...  Montoya Love is recognized by Continental Who,s Who ... Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range of ... healthcare institutions, clinical laboratories and life science researchers with ... globe. ...
(Date:2/4/2016)... 2016  Omnicell, Inc. (NASDAQ: OMCL ), a leading ... systems, today announced results for its fiscal year and ... --> GAAP results: Revenue for the ... million or 4.1% from the third quarter of 2015, ... quarter of 2014. Revenue for the year ended December 31, ...
(Date:2/4/2016)... , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) today ... of Pfizer Inc. and President of Pfizer Global Supply, has ... of February 4, 2016. In addition, the Company announced that ... the audit committee since 2010, has retired from the AMRI ... attention to his other business ventures.  William ...
Breaking Medicine Technology: